Found 35 articles for: "Janus kinase inhibitor"
New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read MoreTreatment of Nail Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 146 | Copyright © February 2022
Nail psoriasis has a considerable negative impact on the quality of life by limiting the patient’s household chores, professional activities and social interactions. Treatment for nail psoriasis...
Read MoreUnderstanding the Potential Role of Abrocitinib in the Time of SARS-CoV-2
July 2021 | Volume 20 | Issue 7 | Editorials | 806 | Copyright © July 2021
ARTICLE: Evolution of Skin Barrier Science for Healthy and Compromised Skin
April 2021 | Volume 20 | Issue 4 | Supplement Individual Articles | s3 | Copyright © April 2021
Skin is a complex organ comprised of multiple cell types and microstructures that work in concert to serve critical functions and support the body’s homeostasis. It is the outermost, cornified l...
Read MoreDermatologists’ Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey
February 2021 | Volume 20 | Issue 2 | Original Article | 126 | Copyright © February 2021
Background: Psoriasis is commonly classified as either mild or moderate to severe, without specific parameters to differe...
Read MoreTopical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis
October 2020 | Volume 19 | Issue 10 | Original Article | 956 | Copyright © October 2020
Mild to moderate atopic dermatitis (AD) occurs frequently in children and adults and is usually managed through the use of pharmacologic treatments, such as topical corticosteroids (TCS) and topical c...
Read MoreDisorders of Hypopigmentation
March 2019 | Volume 18 | Issue 3 | Supplement Individual Articles | 115 | Copyright © March 2019
common cause of depigmentation worldwide is vitiligo. This disorder affects 1-2% of the world’s population and is seen in all races. Vitiligo is an autoimmune disorder in which the predominant cause...
Read MoreTopical Treatment for the Management of Atopic Dermatitis
February 2019 | Volume 18 | Issue 2 | Supplement Individual Articles | 112 | Copyright © February 2019
Atopic dermatitis affects up to 20% of children and continues to increase in prevalence. Effective disease control is aimed at decreasing symptoms and reducing the frequency of flares, which may be co...
Read MoreAn Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review
August 2018 | Volume 17 | Issue 8 | Features | 914 | Copyright © August 2018
KD is an 8 year-old male patient who presented to our clinic in December 2016 with a history of patchy hair loss for many months duration that was worsening. KD’s past medical history was notable fo...
Read MoreSuccessful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib
July 2018 | Volume 17 | Issue 7 | Case Reports | 800 | Copyright © July 2018
Alopecia areata is an autoimmune disease involving the hair follicle with a chronic, relapsing course. Tofacitinib...
Read MoreThe Latest Drugs and Small Molecule Inhibitors for Skin and Hair
December 2017 | Volume 16 | Issue 12 | Original Article | 1224 | Copyright © December 2017
Biologic drugs, a novel class of agents engineered to target specifc mediators of infammation, and small-molecule inhibitors that pen-etrate the cell membrane to interact with targets inside a cell...
Read MoreAggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib
May 2017 | Volume 16 | Issue 5 | Case Reports | 508 | Copyright © May 2017
The Food and Drug Administration approved Ruxolitinib in 2011 for the treatment of primary myelofibrosis. Five-year safety data showed a higher incidence of skin cancer in patients treated with Rux...
Read MoreEmerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib
August 2015 | Volume 14 | Issue 8 | Original Article | 786 | Copyright © August 2015
BACKGROUND: Increased knowledge of the molecular regulatory mechanisms that contribute to the pathogenesis of psoriasis and other inflammatory diseases has created new opportunities for the developmen...
Read MoreRandomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design
August 2015 | Volume 14 | Issue 8 | Original Article | 777 | Copyright © August 2015
Intra-subject, left-right, randomized, controlled study designs are often used for proof-of-concept studies in dermatology. This design was used to evaluate the safety and efficacy of a topical soluti...
Read MoreJAK Inhibitors in Psoriasis: A Promising New Treatment Modality
August 2012 | Volume 11 | Issue 8 | Original Article | 913 | Copyright © August 2012
Background: Inflammatory cytokines play a crucial role in the pathophysiology of psoriasis. New therapies are targeting Janus kinases (JAKs), enzymes involved with transduction of cytokine rece...
Read More
